This article is more than 5 years old. Information may no longer be current.
Konan Medical acquires marketing rights for new VEP technology
Konan Medical USA will bring Neucodia’s EvokeDx, a visual evoked potential device, to market, according to a press release from the company.
The technology, which will allow eye care professionals to assess damage to the visual pathway, has been cleared by the U.S. Food and Drug Administration and includes a patented visual stimulus icVEP, as detailed by Konan Medical.
In the announcement, Konan Medical referred to clinical trial results that were presented at ARVO. The study found that icVEP was 89.2% accurate in differentiating between eyes with glaucoma and normal eyes, according to the release.
“EvokeDx sets a new standard for visual pathway diagnostics with a fantastic user experience and solid clinical performance,” Charles Wm. Stewart, OD, Konan Medical USA CEO, said in the release.
“Where earlier generation products have often left clinicians uncertain of the results, EvokeDx provides graphically clear, statistically evaluated results while being actually enjoyable to use," he continued. "Additionally, EvokeDx is a perfect complement to our RAPDx pupillograph, which also objectively looks at some of the same visual pathways, but from a completely different perspective.”
According to Konan Medical, EvokeDx will be selectively available in the second quarter of 2014.